Viscusi Eugene R, Epelde Francisco, Roca Ruiz Luis Javier, Trillo-Calvo Eva
Department of Anesthesiology, Sidney Kimmel Medical College, Thomas Jefferson University, 111 South 11th Street, Suite 8290, Philadelphia, PA, 19107, USA.
Hospital Universitari Parc Taulí and Autonomous University of Barcelona, Barcelona, Spain.
Pain Ther. 2024 Dec;13(6):1351-1376. doi: 10.1007/s40122-024-00645-y. Epub 2024 Sep 21.
Acute moderate-to-severe pain is common after surgery, trauma, or musculoskeletal injury, but its management remains suboptimal. Current single-agent treatments are limited by safety concerns, narrow therapeutic windows, and abuse potential, leaving substantial unmet needs. Here, we aimed to review guidelines for the management of acute moderate-to-severe post-surgical, trauma-related, or musculoskeletal pain in adults and discuss existing and potential future analgesics in this setting. We searched PubMed to identify relevant guidelines and existing analgesics for acute pain. To identify compounds in development, we searched ClinicalTrials.gov and the European Union Clinical Trials Register. Guidelines universally recognize the limitations of single-agent analgesics (particularly those with a single mechanism of action [MoA]) and recommend a multimodal approach as an established standard for acute pain. The benefit-risk profiles of traditional treatments, including paracetamol (acetaminophen), nonsteroidal anti-inflammatory drugs, selective cyclooxygenase-2 inhibitors, and opioids, can be improved by combining agents targeting different pain pathways. In multimodal approaches, lower doses of constituent agents can be used to achieve the same or superior analgesic effects relative to the individual agents. In some cases, novel formulations and co-crystal technology offer enhanced physicochemical and pharmacokinetic properties over individual agents. Lastly, initiatives to increase patient awareness and education around pain management may improve treatment satisfaction and quality of life, and hasten recovery. In conclusion, management of acute moderate-to-severe pain remains inadequate. Multimodal analgesics may offer advantages over traditional single-agent treatments (that often have a single MoA) for acute moderate-to-severe post-surgical, trauma-related, or musculoskeletal pain in adults. Multimodal analgesics, combined with patient education initiatives and non-pharmacological measures, when necessary, offer promise in addressing unmet needs in this setting.
急性中重度疼痛在手术、创伤或肌肉骨骼损伤后很常见,但其管理仍不尽人意。目前的单药治疗受到安全性问题、狭窄的治疗窗和滥用可能性的限制,仍存在大量未满足的需求。在此,我们旨在回顾成人急性中重度术后、创伤相关或肌肉骨骼疼痛的管理指南,并讨论该情况下现有的和潜在的未来镇痛药。我们检索了PubMed以确定相关指南和现有的急性疼痛镇痛药。为了识别正在研发的化合物,我们检索了ClinicalTrials.gov和欧盟临床试验注册库。指南普遍认识到单药镇痛药(尤其是那些具有单一作用机制[MoA]的药物)的局限性,并推荐多模式方法作为急性疼痛的既定标准。通过联合针对不同疼痛途径的药物,可以改善包括对乙酰氨基酚、非甾体抗炎药、选择性环氧化酶-2抑制剂和阿片类药物在内的传统治疗的效益风险概况。在多模式方法中,相对于单一药物,可以使用更低剂量的成分药物来达到相同或更好的镇痛效果。在某些情况下,新型制剂和共晶技术相对于单一药物具有更好的物理化学和药代动力学特性。最后,提高患者对疼痛管理的认识和教育的举措可能会提高治疗满意度和生活质量,并加速康复。总之,急性中重度疼痛的管理仍然不足。对于成人急性中重度术后、创伤相关或肌肉骨骼疼痛,多模式镇痛药可能比传统的单药治疗(通常具有单一MoA)具有优势。多模式镇痛药与患者教育举措以及必要时的非药物措施相结合,有望满足该情况下未满足的需求。